#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Retinal dystrophy Stress cardiomyopathy Von Willebrand's disease Blastic plasmacytoid dendritic cell neoplasia Homocystinuria Raynaud's phenomenon Myotonic dystrophy Lymphoma Thrombocytosis Round cell liposarcoma Pneumonia Epileptic encephalopathy Sexually transmitted disease Chronic inflammatory demyelinating polyradiculoneuropathy Mantle cell lymphoma refractory More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma Leukoencephalopathy – Basic Information Medulloblastoma – Trials in Disease Mastocytosis – Basic Information Cystic fibrosis lung – Trials in Disease Urea cycle disorder Stevens-Johnson syndrome – Life with Disease Myelodysplastic syndrome – Diagnostics Primary mediastinal large B-cell lymphoma Amyotrophic lateral sclerosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    IHMA-2121771-1 Citric Acid Monohydrate Aticaprant FIBRIN Retifanlimab Mocravimod Tolvaptan Protease Pozelimab Belinostat Emibetuzumab Nicotine FOSFOMYCIN CALCIUM Brentuximab Vedotin Camphor Tislelizumab Glenzocimab 20-HYDROXYECDYSONE Idelalisib Gsk4381562A More therapies…

    Learn about Your Condition

    Polyneuropathy Colonoscopy Antisynthetase syndrome Chronic hepatic failure Duchenne muscular dystrophy Diabetic foot infection Adenocarcinoma gastric Chronic disease Hodgkin's disease recurrent Marfan's syndrome VEXAS syndrome Oedema peripheral Post procedural oedema Chondrosarcoma C3 glomerulopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic spontaneous urticaria

  • Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

    Recruiting

    3 1 1
    Investigated Drugs:
    • Remibrutinib
    Bulgaria Czechia France Germany Poland Spain

  • A study to evaluate the efficacy and safety of lesigercept in adults with chronic spontaneous urticaria who do not have enough relief from antihistamines

    Recruiting

    2 1
    Bulgaria Poland

  • A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

    Recruiting

    2 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Loratadine
    Bulgaria Germany Poland Spain

  • Study of tildrakizumab to treat patients with chronic spontaneous urticaria who did not respond to previous treatments

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Tildrakizumab
    Germany

  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • Study on the Effects of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Placebo
    Bulgaria Germany Hungary Italy Poland Spain
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!